Evidence that host immunity plays a critical role in limiting tumor outgrowth in the early stages of tumorigenesis supports the notion of immune surveillance (1, 2) . However, to effectively function, endogenous or adoptively transferred tumor-specifi c T cells must be present in reasonable numbers, maintain their tumor specifi city and an activated phenotype, traffi c to the tumor site, and kill their targets in situ. Unfortunately, priming tumor-specifi c T cells and sustaining an immune response that imparts a measurable clinical benefi t is limited by the ability of tumors to modify their microenvironment (3) . These immunosuppressive mechanisms are also present in transplantable mouse tumors in which stable cell lines are generated after multiple in vivo passages that ultimately select for clones able to avoid immune recognition. As such, these models represent useful tools to identify the cellular and molecular tumor-induced immunosuppressive pathways, as well as discover pharmacological targets and screen immunomodulatory drugs with measurable antitumor activity.
Extensive data exist in mouse models correlating tumor progression with the accumulation of myeloid inhibitory cells such as CD11b + /Gr-1 + myeloid-derived suppressor cells (MDSCs) (4) , immature dendritic cells (5) , and F4/80 + macrophages (6) that induce local and possibly systemic immunosuppression (7) . l-Arginine metabolism is an important pathway used by MDSCs to blunt antitumor immunity (8) . In these cells, arginase-1 (ARG1) and nitric oxide synthase-2 (NOS2), the key enzymes in l-arginine catabolism, work either alone or synergistically to suppress T cell function (9) . The elimination, functional inhibition, or diff erentiation of MDSCs in tumor-bearing hosts can restore CD8 + T cell
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function
Phosphodiesterase-5 (PDE5) inhibitors (sildenafi l, tadalafi l, and vardenafi l) are agents currently in clinical use for nonmalignant conditions. We report the use of PDE5 inhibitors as modulators of the antitumor immune response. In several mouse tumor models, PDE5 inhibition reverses tumor-induced immunosuppressive mechanisms and enables a measurable antitumor immune response to be generated that substantially delays tumor progression. In particular, sildenafi l, down-regulates arginase 1 and nitric oxide synthase-2 expression, thereby reducing the suppressive machinery of CD11b + /Gr-1 + myeloid-derived suppressor cells (MDSCs) recruited by growing tumors. By removing these tumor escape mechanisms, sildenafi l enhances intratumoral T cell infi ltration and activation, reduces tumor outgrowth, and improves the antitumor effi cacy of adoptive T cell therapy. Sildenafi l also restores in vitro T cell proliferation of peripheral blood mononuclear cells from multiple myeloma and head and neck cancer patients. In light of the recent data that enzymes mediating MDSC-dependent immunosuppression in mice are active also in humans, these fi ndings demonstrate a potentially novel use of PDE5 inhibitors as adjuncts to tumorspecifi c immune therapy.
responsiveness (10, 11) , thereby implicating their role in tumor-induced immunosuppression.
By increasing the intracellular concentrations of cyclic guanosine monophosphate (cGMP), phosphodiesterase-5 (PDE5) inhibitors such as sildenafi l (Viagra), vardenafi l (Levitra), and tadalafi l (Cialis) have been used therapeutically to treat erectile dysfunction (12) , pulmonary hypertension (13) , and cardiac hypertrophy (14) . More recently, they were shown to induce apoptosis in diff erent human tumors such as colon carcinoma and chronic lymphocyte leukemia (15, 16) . In our mouse models, we show that pharmacologic PDE5 blockade down-regulates MDSC suppressive pathways and restores antitumor immunity. Moreover, our in vitro experiments using PBMCs from multiple myeloma (MM) and head and neck cancer patients suggest that the same mechanisms found in mice are also present in humans and demonstrate a possible role for PDE5 inhibitors as an immune adjuvant in the clinical setting.
RESULTS

PDE5 inhibition augments immune-mediated antitumor activity in vivo
When administered in vitro, PDE5 inhibition induces apoptosis in colon carcinoma (15) and chronic lymphocytic leukemia cells (16) . To determine whether similar eff ects could be observed in vivo, we used various transplantable mouse tumors, including CT26WT (a colon carcinoma; Fig. 1 A) , the more aggressive variant C26GM (Fig. 1 B) , TS/A (a mammary adenocarcinoma; Fig. 1 C) , and the MCA203 fi brosarcoma (Fig. 1 D) . PDE5 inhibitors were administered starting on the day of tumor challenge. Sildenafi l and tadalafi l signifi cantly delayed tumor outgrowth by 50 to 70% in immune-competent mice, although all mice ultimately died (Fig. S1 , available at http://www.jem.org/cgi/content/full/ jem.20061104/DC1). Similar results were obtained even if sildenafi l treatment was started on day 7 after tumor challenge in the CT26WT model (Fig. S2) . The fact that no diff erence in tumor outgrowth was seen between early versus late administration of sildenafi l suggests that PDE5 inhibition does not appreciably aff ect the early phases of tumor uptake but rather infl uences the later stages of tumor outgrowth. Because the addition of sildenafi l to cultured CT26WT cells did not increase their apoptosis or aff ect their doubling time (unpublished data), we conclude that sildenafi l does not have a direct antitumor eff ect but rather interferes in host-tumor interactions.
To confi rm that the antitumor eff ect of PDE5 inhibitors was immune mediated, the experiments were repeated in immune-compromised BALB/c-Rag-2 −/− mice (Fig. 1, A-C) . In these hosts, sildenafi l demonstrated no antitumor effi cacy. Because these mice lack T and B lymphocytes but have normal or enhanced NK and NKT activity (17, 18) , these results strongly suggest that the antitumor activity of PDE5 inhibition in our models is primarily caused by an adaptive immune response with either minimal NK/NKT-mediated activity, direct tumor-induced apoptosis, or tumor angiogenesis inhibition.
Evidence of an immune-mediated, antitumor eff ect of PDE5 inhibition is further shown by tetramer analysis on splenocytes obtained from sildenafi l-treated, CT26WT tumorbearing mice, which revealed a higher number of CTLs specifi c for AH-1 (unpublished data), a CT26 tumor-associated antigen, as compared with their untreated counterparts (19) . To confi rm immune-mediated antitumor activity in the sildenafi l-treated groups, we performed an in vivo cytotoxicity assay. BALB/c mice were injected with PBS (naive), vaccinated with γ-irradiated CT26WT or C26GM, or challenged with CT26WT or C26GM tumors on day 0. On day 12 (CT26WT) or day 5 (C26GM), all mice received carboxyfl uorescein diacetate succinimidyl ester (CFSE)-labeled splenocytes pulsed with the MHC class I-restricted AH-1 peptide (CFSE high ), admixed with CFSE-labeled splenocytes pulsed with the irrelevant hemagglutinin (HA)-peptide (CFSE low ). In vivo T cell cytotoxicity was determined 40 h later (Fig. 2) . 
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These time points were chosen based on the kinetics of tumor outgrowth observed in Fig. 1 A and Fig. 1 B, respectively, when tumor size signifi cantly diff ered between untreated and sildenafi l-treated mice. As expected, an endogenous AH1-specifi c immune response was observed in the vaccinated mice as compared with their tumor-bearing counterparts. PDE5 inhibition in the vaccine-primed mice failed to augment antigen-specifi c CD8 responsiveness compared with no treatment. In contrast, tumor-bearing mice treated with sildenafi l early after tumor challenge generated antigenspecifi c immunity that was signifi cantly greater then that observed in their untreated counterparts and similar, or even superior, to that induced by vaccination. Collectively, this is the fi rst indication that PDE5 inhibitors can modulate antitumor immunity. Because the sildenafi l-mediated antitumor immune response does not completely eradicate tumors, tumor escape mechanisms may be associated with their outgrowth. To test this hypothesis, the parental CT26WT cell line, as well as the CT26 tumor removed on day 24 from sildenafi l-treated mice (either AH-1 pulsed or unpulsed), and BALB/c splenocytes were incubated with either AH-1 peptideprimed (Fig. S1 C) or tumor-primed (Fig. S1 D) eff ector T cells. Although eff ector T cells recognized the parental CT26WT line and released IFN-γ in the assay, they failed to recognize the sildenafi l-derived tumor. Its recognition, however, was restored by loading the sildenafi l-derived tumor with the AH-1 peptide. (Fig. S1, C and D) . These results suggest that the immune response in sildenafi l-treated mice does not result in complete tumor eradication but rather in the selection of antigen-escape variants.
PDE5 inhibition synergizes with adoptive cell therapy (ACT) to delay tumor outgrowth Considering that sildenafi l treatment signifi cantly delayed tumor outgrowth but failed to eradicate it, we sought to determine whether combining sildenafi l with tumor-specifi c CD8 + lymphocytes could enhance the therapeutic effi cacy of ACT. 1 d after tumor challenge, C26GM-bearing mice received purifi ed CD8 + T cells derived from mice vaccinated with γ-irradiated C26GM cells. After adoptive transfer of these vaccine-primed CD8 + T cells, the mice were either Tumor-specifi c T cells were transferred on day 1. Sildenafi l treatment was started on day 1. Tumors were surgically removed and weighed (right) either on day 10 (A) or 21 (B). *, P A < 0.00001 by using one-way ANOVA; +, P T < 0.001 by using a paired t test comparing sildenafi l to sildenafi l + ACT groups. Error bar values are shown. treated with sildenafi l or left untreated. Although adoptive transfer alone demonstrates no statistically meaningful antitumor eff ect compared with no treatment (Fig. 3 A) , PDE5 inhibition signifi cantly reduces tumor outgrowth. However, coupling adoptive immunotherapy with PDE5 inhibition resulted in the greatest antitumor eff ect.
To extend this fi nding to other models, the experiment was repeated using the 4T1 mammary carcinoma genetically modifi ed to express the infl uenza-derived HA as a model tumor antigen (Fig. 3 B) . Mice were challenged on day 0 with 0.5 × 10 6 4T1-HA cells. On the next day they received 3 × 10 6 HA-specifi c naive CD8 + T cells. After adoptive transfer, the mice were either treated with sildenafi l or left untreated. As with the C26GM experiments, no therapeutic benefi t was observed with ACT alone, whereas sildenafi l + ACT imparted the greatest antitumor benefi t. Sildenafi l treatment alone, instead, substantially delayed tumor progression in immunocompetent BALB/c mice but not in immune-defi cient Rag-2 −/− mice (Fig. S3 , available at http://www.jem.org/cgi/ content/full/jem.20061104/DC1). These data confi rm the immunomodulatory properties of PDE5 inhibitors in augmenting the therapeutic effi cacy of ACT and demonstrate a role of sildenafi l in modifying the tumor microenvironment rendering it more susceptible to CTL-mediated cytotoxicity.
PDE5 inhibition increases tumor-infi ltrating CD8 + T cells
To exert a measurable antitumor eff ect, tumor-specifi c T cells must be present in suffi cient numbers and capable of traffi cking to their targets. A direct correlation exists between the number of tumor-infi ltrating lymphocytes (TILs) and a favorable clinical outcome, as demonstrated in patients with metastatic ovarian cancer (20) . Furthermore, the functional status of TILs has been correlated with a favorable prognosis in various human malignancies (20) (21) (22) (23) (24) . Because PDE5 inhibition augments antitumor immunity, we asked whether sildenafi l treatment altered both the number and activation state of TILs. Histological examination of CT26WT tumors revealed a greater intratumoral cellular infi ltrate in the sildenafi l-treated mice compared with the untreated controls (Fig. 4 A) . To better evaluate these diff erences, C26GM-bearing mice received either tumor-primed or no T cells followed by sildenafi l treatment or no additional therapy. The tumors were excised 9 d later, and single cell suspensions were obtained. The T cell infi ltrate was analyzed by fl ow cytometry for CD4 + and CD8 + T cells. This approach enabled us to accurately examine the entire tumor mass and reliably quantify the infi ltrating lymphocytic population. Although no increase in CD4 + T cells was observed with PDE5 inhibition (Fig. 4 B, inset), sildenafi l treatment greatly increased CD8 + intratumoral infi ltration with up-regulation of the activation markers CD69 and CD25 (Fig. 4 C) . There were no diff erences in activation markers between the sildenafi l-treated group and sildenafi l + ACT, whereas a signifi cant increase in intratumoral T cells were observed in the sildenafi l + ACT-treated group compared with sildenafil alone ( To determine whether the immunomodulatory eff ect of PDE5 inhibition aff ected T cell activation within the tumor microenvironment, we examined IL-2 production by TILs using a transgenic mouse in which expression of GFP is under an IL-2 promoter (BALB/c-IL-2p/GFP) (25) . In this model, T cell stimulation activates the IL-2 promoter and results in expression of the reporter transgene, GFP, which is easily detectable by fl ow cytometry. C26GM-primed BALB/ c-IL-2p/GFP splenocytes were adoptively transferred into tumor-bearing recipients that were either left untreated or treated with sildenafi l for 9 d. Single cell suspensions of the tumor-infi ltrating CD8 + T cells were analyzed by fl ow cytometry for GFP expression. Adoptively transferred, vaccineprimed T cells were activated in the tumor microenvironment only in the presence of PDE5 inhibition, whereas in its absence they produced no IL-2 and, hence, were bona fi de anergic T cells (Fig. 4 D) . To further prove that these eff ects were dependent on CD8 + T cells, mice were challenged with C26GM and were (a) left untreated, (b) given sildenafi l, (c) given an anti-CD8 + depleting antibody, or (d) given both sildenafi l and the CD8 + depleting antibody. Sildenafi l treatment again demonstrated a statistically signifi cant reduction in tumor outgrowth, an eff ect completely abrogated by CD8 + depletion (Fig. 4 E) . These experiments demonstrate that PDE5 inhibition enhances the tumor-specifi c T cell response, increases intratumoral T cell infi ltration and activation, and underscores the role of CD8 + T cells in sildenafi l-mediated antitumor responses.
In vitro sildenafi l down-regulates the myeloid suppressor cell suppressive marker IL-4R
The experiments described thus far demonstrate the ability of PDE5 inhibition to prime/augment antitumor immunity. Yet the mechanisms resulting in T cell activation are unknown. Because PDE5 is expressed in various cells of the immune system (including DCs, macrophages, and T cells [26] ), PDE5 inhibitors could putatively target these various populations. Furthermore, numerous factors are present in tumor-bearing hosts that could impair the generation of an eff ective immune response such as the defective maturation of DCs (7), the accumulation of suppressive MDSCs (4), T cell anergy (27) , and/or the accumulation of T reg cells (28) . These populations were, therefore, examined separately. Flow cytometric analysis of sildenafi l-treated or untreated mice failed to reveal important diff erences in DC maturation, CD4 + Foxp3 + T reg cells, or CD11b + /Gr-1 + MDSC accumulation (unpublished). We evaluated the eff ect of in vitro PDE5 inhibition on purifi ed CD11c + , CD11b + , CD4 + , and CD8 + cells isolated from C26GM tumor-bearing mice. This enabled us to examine purifi ed populations, thereby eliminating the potential for exogenous infl uences. Although sildenafi l treatment increased the intracellular concentration of cGMP in all the populations examined (Fig. 5 A) , it had no eff ect on the proliferation of purifi ed CD4 + and CD8 + T cells stimulated with either ConA (Fig. 5 B) or anti-CD3/CD28 beads ( varies among populations of MDSCs isolated from diff erent organs, with intratumoral MDSCs being the most immunosuppressive. Interestingly, these MDSCs express greater levels of NOS2 and ARG1 than their splenic counterparts (5). ARG1 expression is mainly regulated by the STAT-6-IL-4Rα pathway (30) . We recently correlated IL-4Rα expression on CD11b + /Gr-1 + with an immunosuppressive phenotype (29) , and our in vitro data (Fig. 5) indicate that sildenafi l down-regulates IL-4Rα on MDSCs. We then asked whether in vivo PDE5 inhibition reduced ARG1 and NOS2 and down-regulated IL-4Rα in tumor-associated MDSCs. BALB/c mice were challenged with CT26WT, and half were treated with sildenafi l. Mice were killed 15 d later, and intratumoral MDSCs were obtained. Sildenafi l increased cGMP (Fig. 6 A) , reduced IL-4Rα expression (Fig. 6 B) , and down-regulated NOS2 and ARG1 expression and reduced their enzymatic activity in the intratumoral MDSCs (Fig. 6,  C and D) . Considering that ARG1 and NOS2 are key enzymes in MDSC suppressive pathways (8, 31) , these fi ndings support the hypothesis that PDE5 inhibition is a novel pharmacologic approach to regulate MDSC-mediated immunosuppressive pathways.
Gr-1 + cells are known to facilitate tumor outgrowth. As such, it is conceivable that strategies seeking to eliminate this population may have a measurable antitumor eff ect. In certain tumor models, the Gr-1 depleting antibody inhibited tumor outgrowth even in the absence of T cells, although the antitumor eff ect was more pronounced in immune competent mice (32, 33) . In light of these results and to verify that MDSCs are the target of sildenafi lmediated antitumor activity, we examined the eff ect of antibody-mediated MDSC depletion in combination with PDE5 inhibition in vivo. BALB/c mice were challenged on day 0 with C26GM tumor and were (a) left untreated; 
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(b) injected with 100 μg of anti-Gr-1 antibody i.p. on days 0, 3, and 6; (c) treated with sildenafi l; or (d) treated with a combination of the two treatments. As shown in Fig. 6 E, Gr-1 depletion delayed tumor outgrowth similarly to PDE5 inhibition, whereas no synergistic eff ect was seen with the combination. Collectively, these data demonstrate the immunosuppressive nature of Gr-1 + cells and the ability of PDE5 inhibition to reduce their suppressive phenotype in vivo.
PDE5 inhibition abrogates MDSC suppressive activity
Freshly isolated MDSCs suppress the in vitro proliferation of activated lymphocytes. Interestingly, the suppressive mechanisms appear to be strain specifi c. In the Th1 cell prone strain C57BL/6, it is mediated by NOS2 through NO production (34), whereas, in the mixed Th1/Th2 cell BALB/c strain, suppression requires peroxynitrite formation via ARG1 and NOS2 coexpression (8) or l-arginine depletion secondary to ARG1 overexpression (35) . Reductions of both ARG1 and NOS2 expression via PDE5 inhibition should aff ect both suppressive pathways, resulting in less MDSC-mediated immunosuppression and, therefore, enhanced antigen-specifi c T cell proliferation. To test this hypothesis, tumor-derived CD11b + MDSCs were isolated from C26GM-bearing BALB/c mice. MDSC suppressive activity was determined by admixing MDSCs with CFSE-labeled HA-specifi c CD8 + (clone 4) or CD4 + (6.5) T cells pulsed with their relevant peptide in the presence or absence of sildenafi l (Fig. 7, A and B) . Although the addition of tumor-derived MDSCs significantly impaired antigen-specifi c T cell proliferation as demonstrated by the low percentage of CFSE low clonotypic T cells, sildenafi l almost completely restored both CD4 + and CD8 + responsiveness of these antigen-specifi c T cells. The absence of sildenafi l-mediated enhancement in T cell function in the groups lacking CD11b + cells underscores the targeted role of sildenafi l on the MDSC population. Because in a Th1 cell-prone environment MDSC suppression is only NOS2 dependent (34), we examined the role of PDE5 in MDSCs in a C57BL/6 background where NOS2 −/− mice are also available. CD11b + MDSCs were isolated from either C57BL/6-NOS2 +/+ or B16GM-bearing C57BL/6-NOS2 −/− B16GM melanoma-bearing mice. A suppression assay was performed by stimulating OVAspecifi c CD4 + T cells with the relevant peptide in the presence or absence of MDSCs obtained from either NOS2 +/+ or NOS2 −/− tumor-bearing mice (Fig. 7 C) . Although the addition of C57BL/6-NOS2 +/+ MDSCs induced considerable T cell suppression, no suppression was observed with MDSCs from NOS2 −/− mice. Furthermore, although PDE5 inhibition reversed MDSC suppression in NOS2 +/+ mice, sildenafi l failed to augment T cell responsiveness in the NOS2 −/− -derived MDSC suppression assay. These results confi rm the role of NOS2 in MDSC-mediated T cell suppression (Fig. 7 C) and underscore the ability of PDE5 inhibition to reverse the two major suppressive pathways in MDSCs (ARG1 and NOS2).
PDE5 inhibition restores T cell proliferation in MM and head and neck cancer patients
Having demonstrated that PDE5 inhibition can impair MDSC suppressive mechanisms in BALB/c and C57BL/6 tumor-bearing mice, we next sought to determine whether similar results could be obtained in humans. Head and neck cancers are known to be highly immunosuppressive. Their high levels of GM-CSF production are likely the major mediator of immune suppression observed in these patients and are probably responsible for the intratumoral infi ltration by MDSCs (36) . In fact, peripheral blood lymphocytes (PBLs) from these patients are functionally impaired in their ability to be activated and to proliferate upon stimulation (37) . Similar results were also seen in prostate cancer (38) and in nonsmall cell cancer (35) . Although this anergic state in solid tumors may be attributable to the ARG1-and/or NOSdependent suppressive activity of MDSCs, MDSC-mediated immunosuppression has not been previously reported in hematological malignancies. PBMCs from MM patients were stimulated with anti-CD3/CD28 antibody-coated beads in the presence of N-(omega)-hydroxy-nor-l-arginine (NorNOHA; an ARG1-specifi c inhibitor), N G -monomethyl-l-arginine (l-NMMA; an NOS2 inhibitor), both inhibitors, or neither. As shown in Fig. 8 A (top) , T cell expansion was considerably enhanced in the presence of both NorNOHA and l-NMMA, whereas the single inhibitors failed to increase T cell proliferation over the baseline. Interestingly, sildenafi l yielded results equivalent to the combination of NorNOHA and l-NMMA. These results suggest involvement of both ARG1 and NOS2 in MDSC-mediated immunosuppression in myeloma and confi rm the in vitro results demonstrating the ability of PDE5 inhibitors to aff ect both pathways. Recent data from our lab identifi ed human MDSCs as ARG + , CD14 + cells (unpublished data). We therefore examined T cell expansion in CD14 + -depleted PBMCs under the same conditions (Fig. 8 A, bottom) . Although CD14 + depletion alone increased CD3 + T cell expansion fourfold, pharmacologic inhibitors failed to further enhance proliferation, suggesting that CD14 + cells are the mediators of ARG1-and NOS2-mediated immunosuppression in MM. As seen with purifi ed mouse T cells (Fig. 5 B) , sildenafi l also failed to enhance the CD3 + T cell proliferation of CD14-depleted PBMCs from cancer patients.
We next sought to determine whether we could restore T cell proliferation of PBMCs isolated from head and neck and MM patients stimulated with anti-CD3/CD28 antibody-coated beads in the presence or absence of sildenafi l. The expansion of CD4 + and CD8 + T cells obtained from MM or head and neck patients was signifi cantly less than that observed using healthy donors (Fig. 8 B) . In contrast, in the presence of sildenafi l, PBMCs from MM and head and neck patients expanded similarly to sildenafi ltreated PBMCs from healthy donors (Fig.8 B) . Interestingly, qualitative diff erences in T cell expansion emerged between the two malignancies. In head and neck patients, CD8 + T cell proliferation is restored with PDE5 inhibition while CD4 + lymphocyte expansion in the same condition is only partially augmented. In contrast, CD4 + T cell proliferation is restored and minimal eff ects are seen on CD8 + lymphocyte expansion with PDE5 blockade in myeloma (Fig. 8 B) .
In summary, these data confi rm that PDE5 inhibition can augment immune responsiveness through its effect on an accessory CD14 + population. Moreover, they suggest that the same immunosuppressive mechanisms found in mice are conserved in human malignancies and that PDE5 can be a useful therapeutic approach to enhance tumorspecifi c immunotherapy.
D I S C U S S I O N
This is the fi rst demonstration that PDE5 blockade exerts an indirect, immune-mediated, antineoplastic eff ect through inhibition of MDSC-mediated immunosuppressive mechanisms. These fi ndings could establish a new role for PDE5 
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inhibition as a viable and eff ective immunological adjunct in the treatment of various malignancies, thereby adding to the growing list of therapeutic applications of these agents. In this paper we show that PDE5 inhibition can signifi cantly overcome the immunosuppressive mechanisms present in a tumor-bearing host to generate immune responses that are similar to (if not greater than) those observed in a nontumor-bearing, vaccine-primed host (Fig. 2) . However, although a CTL response can be elicited, PDE5 blockade is incapable of complete tumor eradication (Fig. S1 ). Several hypotheses may account for these fi ndings. For example, chronic sildenafi l blockade may up-regulate PDE5 expression, making it diffi cult to achieve complete and long-term pharmacologic inhibition (39) . Alternatively, the sildenafi lmediated immune response against the self tumor-associated antigen can predominantly involve low affi nity CD8 + T cells incapable of complete tumor cell killing. Finally, the tumorspecifi c immune response may ultimately result in immune editing of the tumor that escapes immune recognition (Fig.  S1, C and D) .
PDE5 blockade not only increases intratumoral CD8 + infi ltration and activation but also enhances their tumoricidal activity (Fig. 2) . The ability to favorably alter the intratumoral microenvironment, thereby permitting tumor-specifi c T cells to directly interact with their targets, is critical for maximal antitumor immunity. Eff ective immunotherapy requires tumor-specifi c CTLs to infi ltrate the tumor and kill their target in situ. Although no clinical advantage was derived by the presence of tumor-specifi c CTLs in the peripheral blood in melanoma patients (40) , their frequency in the tumor correlated with a favorable prognosis (41) . These clinical observations seem to be confi rmed in our model where sildenafi l treatment (a) increased the CD8 + T cell tumor infi ltration (Fig. 4 B) and (b) increased the percentage of activated T cells (Fig. 4, C and D) . Moreover, the number of tumor-infi ltrating T cells directly correlated with a measurable antitumor eff ect (Fig. 3) .
Although sildenafi l can increase cGMP in T cells, DCs, and CD11b + cells (Fig. 5) , the following data indicate that Gr-1 + /CD11b + MDSCs are its primary cellular target. Gr-1 depletion does not augment sildenafi l-mediated antitumor activity (Fig. 6 E) , and sildenafi l down-regulates MDSC suppressive pathways in vivo (Fig. 6, B-D) . Moreover, sildenafi l reverses MDSC suppression in vitro (Fig. 7) . MDSCs and/or tumor-associated macrophages have been shown to induce apoptosis or anergy in CD8 + and CD4 + T cells through NOS2-and/or ARG1-dependent mechanisms (34) . In fact, NO production anergizes Th1 cells through inhibition of IL-2 signaling (34). Alternatively, in a mixed Th1/Th2 cell environment where ARG-induced pathways also mediate immunosuppression, MDSCs produce NO and super-oxide radicals to generate peroxynitrites that induce apoptosis of activated CD8 + T cells (9) . A greater understanding of the role of MDSCs in tumor-induced immune dysfunction (7, 42) will establish the scientifi c rationale for a targeted pharmacologic approach to disrupt these suppressive mechanisms and may serve as an adjunct to immunotherapy. We previously showed that nitroaspirin could abrogate the inhibitory activity of MDSCs by enhancing the preventive and therapeutic effi cacy of antitumor vaccines (43) . However, despite its use as a vaccine adjuvant, nitroaspirin demonstrated no antitumor effi cacy when used alone. In contrast, downmodulation of both ARG1 and NOS2 in MDSCs (Fig. 6 ) with PDE5 inhibitors eff ectively abrogates MDSC-mediated immune suppression, resulting in a measurable antitumor response (Fig. 1, Fig. 3, and Fig. 4) . We have recently shown that to eff ectively exert their suppressive function, MDSCs must (a) be activated by IFN-γ production from antigenstimulated T cells, (b) release their own IFN-γ, and (c) be responsive to IL-13 (29) . Cooperation between these two cytokines leads to the activation of ARG1 and NOS2 enzymes. Sildenafi l neither alters IFN-γ production from activated lymphocytes (not depicted) nor changes IL-13 and IFN-γ production from MDSCs (Fig. S6 , available at http://www.jem.org/cgi/content/full/jem.20061104/DC1). Rather, PDE5 inhibition down-regulates IL-4Rα expression on MDSCs (Fig. 5 and Fig. 6 ), likely impairing their responsiveness to IL-13.
MDSCs can promote tumor growth not only by preventing tumoricidal CTL activity but also by supporting tumor angiogenesis. The Gr-1 + /CD11b + cells, in fact, produce high levels of the matrix metalloprotease 9, which regulates the bioavailability of vascular endothelial growth factor. The selective deletion of the matrix metalloprotease 9 gene in these cells abolishes their ability to promote tumor growth and inhibits tumor formation (44) . Although PDE5 inhibition could also aff ect these proangiogenic mechanisms, the lack of antitumor activity in sildenafi l-treated Rag-2 −/− mice ( Fig. 1 ) and the dependence on CD8 + T cells (Fig. 4) would imply otherwise.
Although we have shown that PDE inhibitors reduce NOS2 and ARG1, the full mechanisms underlying these eff ects remain to be elucidated. One putative mechanism involves the impact of these inhibitors on mRNA stability. cGMP destabilizes NOS2 mRNA by reducing the ubiquitous mRNA binding protein, human antigen R (45) . As such, destabilization of NOS2 mRNA via PDE5 inhibition would abrogate NO-mediated immunosuppression more eff ectively than would competitive inhibition of NO itself. However, because ARG1 mRNA does not possess adenylate/ uridylate-rich elements and has not been described to be stabilized by human antigen R, other mechanisms are likely involved in PDE5-mediated down-regulation of ARG1. One possibility is that high levels of cGMP induced by PDE5 blockade reduce the cytosolic Ca 2+ concentration (46) , leading to a reduction of the calcium-dependent protein kinase C activity (47) that in turn prevents up-regulation of IL-4Rα (48) . The link between IL-4Rα and ARG1 in MDSCs is supported by recent data (29) demonstrating a direct correlation between ARG1 expression and IL-4Rα expression. ACT of tumor-primed CD8 T cells completely eradicated a preestablished C26GM tumor in the LysM Cre IL-4Rα −/fl ox mice in which IL-4Rα expression has been deleted in neutrophils and macrophages, whereas no eff ect was seen in the control littermates (29) . Our fi ndings support these data by demonstrating that PDE5 blockade down-regulates IL-4Rα expression on tumor-infi ltrating MDSCs (Fig. 6 ) and synergizes with the adoptive transfer of tumor-primed CD8 + T cells (Fig. 3 and Fig. 4 ). This eff ect appears to specifi cally target MDSCs, because IL-4Rα expression on isolated CD11b + cells from tumor-bearing mice is signifi cantly reduced when co-cultured in the presence of sildenafi l (Fig. 5) . Collectively, these fi ndings underscore the critical role of the IL-4Rα-ARG1 pathway in MDSCs, as well as the use of PDE5 inhibitors as therapeutically eff ective drugs to overcome tumor-induced immunosuppression.
Although most of the work to date on MDSCs has focused on mouse Gr-1 + /CD11b + cells, emerging data confi rm the presence of these cells in human malignancies (7, 42, 49) . In this paper we show that a nonlymphoid CD14 + population mediates the hypo-responsiveness in PBLs from MM patients. Although the low proliferative capacity may be caused by intrinsic T cell defects, an additional explanation for T cell unresponsiveness is the presence of a nonlymphoid suppressor population whose function is abrogated by PDE5 inhibition. Evidence supporting this is the ability of sildenafi l to augment the proliferative index of lymphocytes obtained from unfractionated PBMCs but not from purifi ed CD4 + or CD8 + T cells (Fig. 8 and Fig. S6 ). The ability of sildenafi l to restore proliferation of PBLs from both head and neck and myeloma patients suggests that the mechanisms found in mice also play a major role in cancer-mediated immunosuppression in two very diff erent human malignancies.
Although drugs such l-NMMA, Nor-NOHA, NO-aspirin, or Vitamin D3 (4) have all been used in vitro and in mouse models to alter MDSC suppressive mechanisms, they have either not been extensively tested in humans or have been found to be extremely toxic, as is the case with l-NMMA (50) . In demonstrating the ability to use clinically available PDE5 inhibitors to overcome the MDSC-mediated immunosuppressive pathways, these observations open the opportunity for the rapid translation of our preclinical fi ndings into the clinic and give new hope for the development of more eff ective immunebased treatments for a broad range of human malignancies.
MATERIALS AND METHODS
Cell lines.
The following cell lines were used: CT26, a carcinogen-induced, undiff erentiated colon carcinoma obtained from BALB/c mice (51); TS/A, a mouse mammary adenocarcinoma derived from BALB/c mice (52); MCA203, a C57BL/6-derived fi brosarcoma (53); and B16-GM, a C57BL/6 melanoma cell line genetically modifi ed to secrete GM-CSF (54). The 4T1-HA cell line was obtained by lentiviral transduction of 4T1 mammary carcinoma and was provided by K. Whartenby (Johns Hopkins University, Baltimore, MD). These cell lines were grown in DMEM or RPMI 1640 (Invitrogen) with 10% FBS (Invitrogen). The C26GM cell line derived from the C26 colon carcinoma was genetically modifi ed to produce GM-CSF (8) and was grown in the presence of 800 μg/ml G418.
Drugs and cytokines.
Sildenafi l (Pfi zer) was dissolved in the drinking water (20 mg/kg/24 h), given i.p. daily where indicated (20 mg/kg/24 h), or added to the cell cultures (50 mg/ml). 2 mg/kg/24 h tadalafi l (Lilly ICOS) was administered i.p. In vivo treatments started on day 0 unless otherwise indicated.
NorNOHA and l-NMMA (Calbiochem) were used at 500 μM in vitro.
Mice and in vivo experiments. Vaccination and ACT. The vaccine consisted of 10 6 γ-irradiated CT26 or C26GM cells injected s.c. For ACT experiments, mice were vaccinated on days −14 and −7 before ACT in all four limbs with 10 6 γ-irradiated C26GM. The CD8 + T cells were negatively purifi ed using the CD8 + isolation kit (Miltenyi Biotec), and 3 × 10 6 CD8 + T cells were transferred per mouse. In the 4T1-HA experiments, HA-specifi c CD8 + naive T cells were isolated from spleens and lymph nodes of pCL4-TCR mice.
Flow cytometry. Single cell suspensions from spleens or tumors were stained with PE-conjugated anti-mouse CD8 (CD8-PE; BD Biosciences), allophycocyanin-conjugated anti-mouse CD4 (CD4-allophycocyanin; BD Biosciences), FITC-conjugated anti-mouse CD11c, PE-conjugated antimouse B7.2, cychrome (Cy)-conjugated anti-mouse MHC class II, or with allophycocyanin-conjugated anti-mouse CD11b (BD Biosciences) and PEconjugated anti-mouse Gr-1 (CD8-PE). IL-4Rα expression was determined on purifi ed CD11b + cells with PE-conjugated anti-mouse CD124 (BD Biosciences). Isotype-matched antibodies were used as controls, and live cells were gated based on 7-amino-actinomycin D, annexin V staining. Samples were run on a fl ow cytometer (FACSCalibur; BD Biosciences), and the data were analyzed using FCSexpress software (v 2.0; De Novo Software).
Cell purifi cation. CD11b + purifi cation was performed with mouse CD11b MicroBeads (Miltenyi Biotec). The positive and negative fractions were sorted with the LS columns according to the manufacturer's instructions. CD11c + cells were positively selected from splenocytes of tumor-bearing mice using mouse CD11c MicroBeads (Miltenyi Biotec). CD4 + or CD8 + T cells were negatively selected, using the CD4 + or CD8 + T cell isolation kit (Miltenyi Biotec), from CD11b-depleted splenocytes. CD14 depletion of ARTICLE human PBMCs was obtained by adding PE-labeled, anti-human CD14 antibody (BD Biosciences). The CD14-negative population was collected using a cell sorter (FACSVantage SE; BD Biosciences).
Suppressive assay. 2 × 10 5 purifi ed splenic or intratumoral CD11b + cells were added to 10 6 clonotypic CFSE-labeled splenocytes. They were then peptide pulsed and cultured for 3 d in 96-well fl at-bottom plates. Sildenafi l was added where indicated in the fi gures.
Proliferation assay. PBLs were obtained from MM or head and neck cancer patients after obtaining informed consent using an Institutional Review Board-approved protocol. Ficolled PBMCs were stimulated with anti-CD3/28 antibody-coated Dynal beads (3:1 bead/T cell ratio) for 5 d in a 96-well round-bottom plate and analyzed by fl ow cytometry. Sildenafi l was added where indicated in the fi gures. Results are reported as fold change (number of activated cells/number of unactivated cells).
cGMP. cGMP was measured on purifi ed CD11b + , CD11c + , CD4 + , or CD8 + cells using the Cyclic GMP EIA kit (Cayman Chemical). Data analysis was performed with the workbooks available at http://www. caymanchem.com/neptune/servlet/neptune/template/analysis%2CEIA.vm/a/z. Data are expressed as mean ± SE of quadruplicate wells.
Western blot.
Lysates from purifi ed cells were denaturated at 95°C for 10 min and subjected to SDS-PAGE, and proteins were transferred overnight to polyvinylidene difl uoride membranes. The membranes were incubated with a rabbit polyclonal anti-NOS2 antibody (Santa Cruz Biotechnology, Inc.), mouse anti-ARG1 antibody (a gift from Augusto C. Ochoa, Louisiana State University, New Orleans, LA), or a polyclonal rabbit anti-actin antibody (Sigma-Aldrich). Proteins were detected using the SuperSignal West Pico Chemiluminescent Substrate kit (Pierce Chemical Co.) according to the manufacturer's instructions.
NO measurement. NO was measured using a nitrate/nitrite assay kit (Cayman Chemical) according to the manufacturer's instructions. Results were normalized to 10 6 cells. Data are from triplicate wells.
Arginase assay. The arginase assay was performed as previously described (8) on purifi ed intratumoral MDSCs.
Statistical analysis.
Bivariate Pearson and analysis of variance (ANOVA) analyses were performed using SPSS (v 7.0). All experiments were repeated at least twice, and all p-values were two sided (t test) or one sided (ANOVA).
Online supplemental material. Fig. S1 shows that PDE-5 inhibitors reduce tumor growth but that persistent tumors show evidence of immune editing. In Fig. S2 , the antitumor eff ect of sildenafi l is maintained even with delayed treatment. Fig. S3 shows that sildenafi l increases CD8 + TILs. Fig. S4 depicts sildenafi l as it fails to induce an antitumor eff ect in 4T1-HA-bearing Rag-2 −/− mice. In Fig. S5 , sildenafi l fails to augment proliferation of purifi ed T cells. Fig. S6 shows that sildenafi l does not alter IL-13 or IFN-γ production from CD11b + cells. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20061104/DC1.
